Awaiting development: Guidance and quality standards

Showing 321 to 330 of 344

Guidance and quality standards awaiting development
Title	Type
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance
Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]	Technology appraisal guidance
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Vamikibart for treating uveitic macular oedema [ID6671]	Technology appraisal guidance
Veligrotug for treating thyroid eye disease [ID6636]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance